Poor outcome in adolescents with high-risk Hodgkin lymphoma

International Journal of Oncology

Volumn 33, Issue 1, 2008, Pages 145-151

  Herbertson, R A ^a   Evans, L S ^a   Hutchinson, J ^a   Horsman, J ^a   Hancock, Barry W ^a  

^a WESTON PARK HOSPITAL   (United Kingdom)

Author keywords

Adolescents; Hodgkin lymphoma; Outcome; Young adults

Indexed keywords

BLEOMYCIN; CHLORAMBUCIL; CHLORMETHINE; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; METHOTREXATE; PREDNISOLONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE;

ADOLESCENT; ADOLESCENT HEALTH; ADULT; AGE DISTRIBUTION; ARTICLE; CANCER CLASSIFICATION; CANCER GROWTH; CANCER RISK; CANCER SURVIVAL; CONTROLLED STUDY; HIGH RISK PATIENT; HODGKIN DISEASE; HUMAN; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; SURVIVAL RATE; SURVIVAL TIME; TREATMENT OUTCOME; AGE; MORTALITY; RETROSPECTIVE STUDY; RISK;

ADOLESCENT; ADULT; AGE FACTORS; HODGKIN DISEASE; HUMANS; RETROSPECTIVE STUDIES; RISK;

EID: 51049095165     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo.33.1.145     Document Type: Article

References (34)

1. Albritton K and Bleyer W: The management of cancer in the older adolescent. Eur J Cancer 39: 2594-2599, 2003.
2. Herbertson R and Hancock B: Hodgkin lymphoma in adolescents. Cancer Treat Rev 31: 339-360, 2005.
3. Gatta G, Capocaccia R, De Angelis R, et al: Cancer survival in European adolescents and young adults. Eur J Cancer 39: 2600-2610, 2003.
4. Yung L, Smith P, Hancock BW, et al: Long-term outcome in adolescents with Hodgkin's lymphoma: poor results using regimens designed for adults. Leuk Lymphoma 45: 1579-1585, 2004.
5. Foltz LM, Song KW and Connors JM: Hodgkin's lymphoma in adolescents. J Clin Oncol 24: 2520-2526, 2006.
6. Stiller C: Epidemiology of cancer in adolescents. Med Pediatr Oncol 39: 149-155, 2002.
7. Cotterill SJ, Parker L, Malcolm AJ, et al: Incidence and survival for cancer in children and young adults in the north of England, 1968-1995: a report from the Northern Region Young Persons' Malignant Disease Registry. Br J Cancer 83: 397-403, 2000.
8. Percy CL SM, Linet M, Gloeckler Ries LA and Friedman DL: Lymphomas and reticuloendothelial neoplasms. In: Cancer Incidence and Survival among Children and Adolescents. Ries LAG SM, Gurney JG, Linet M, Tamra T, Young JL and Bunin GR (eds). United States SEER Program 1975-1995, National Cancer Institute, SEER Program, Edition Bethesda, MD, NIH Pub No. 99-4649, 1999.
9. Schellong G, Potter R, Bramswig J, et al: High cure rates and reduced long-term toxicity in pediatric Hodgkin's disease: the German-Austrian multicenter trial DAL-HD-90. The German-Austrian Pediatric Hodgkin's disease study group. J Clin Oncol 17: 3736-3744, 1999.
10. Diehl V, Thomas RK and Re D: Part II: Hodgkin's lymphoma-diagnosis and treatment. Lancet Oncol 5: 19-26, 2004.
11. Cramer P and Andrieu JM: Hodgkin's disease in childhood and adolescence: results of chemotherapy-radiotherapy in clinical stages IA-IIB. J Clin Oncol 3: 1495-1502, 1985.
12. Weiner MA, Leventhal BG, Marcus R, et al: Intensive chemotherapy and low-dose radiotherapy for the treatment of advanced-stage Hodgkin's disease in pediatric patients: a Pediatric Oncology Group study. J Clin Oncol 9: 1591-1598, 1991.
13. Donaldson SS, Hudson MM, Lamborn KR, et al: VAMP and low-dose, involved-field radiation for children and adolescents with favorable, early-stage Hodgkin's disease: results of a prospective clinical trial. J Clin Oncol 20: 3081-3087, 2002.
14. Weiner MA, Leventhal B, Brecher ML, et al: Randomized study of intensive MOPP-ABVD with or without low-dose total-nodal radiation therapy in the treatment of stages IIB, IIIA2, IIIB and IV Hodgkin's disease in pediatric patients: a Pediatric Oncology Group study. J Clin Oncol 15: 2769-2779, 1997.
15. Hutchinson RJ, Fryer CJ, Davis PC, et al: MOPP or radiation in addition to ABVD in the treatment of pathologically staged advanced Hodgkin's disease in children: results of the children's cancer group phase III trial. J Clin Oncol 16: 897-906, 1998.
16. Hudson MM, Greenwald C, Thompson E, et al: Efficacy and toxicity of multiagent chemotherapy and low-dose involved-field radiotherapy in children and adolescents with Hodgkin's disease. J Clin Oncol 11: 100-108, 1993.
17. Friedmann AM, Hudson MM, Weinstein HJ, et al: Treatment of unfavorable childhood Hodgkin's disease with VEPA and low-dose, involved-field radiation. J Clin Oncol 20: 3088-3094, 2002.
18. Oberlin O, Leverger G, Pacquement H, et al: Low-dose radiation therapy and reduced chemotherapy in childhood Hodgkin's disease: the experience of the French Society of Pediatric Oncology. J Clin Oncol 10: 1602-1608, 1992.
19. Landman-Parker J, Pacquement H, Leblanc T, et al: Localized childhood Hodgkin's disease: response-adapted chemotherapy with etoposide, bleomycin, vinblastine, and prednisone before low-dose radiation therapy-results of the French Society of Pediatric Oncology Study MDH90. J Clin Oncol 18: 1500-1507, 2000.
20. Nachman JB, Sposto R, Herzog P, et al: Randomized comparison of low-dose involved-field radiotherapy and no radiotherapy for children with Hodgkin's disease who achieve a complete response to chemotherapy. J Clin Oncol 20: 3765-3771, 2002.
21. Radford JA, Rohatiner AZ, Ryder WD, et al: Ch1VPP/EVA hybrid vs. the weekly VAPEC-B regimen for previously untreated Hodgkin's disease. J Clin Oncol 20: 2988-2994, 2002.
22. Canellos GP, Anderson JR, Propert KJ, et al: Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 327: 1478-1484, 1992.
23. Diehl V, Franklin J, Pfreundschuh M, et al: Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med 348: 2386-2395, 2003.
24. Hancock BW, Gregory WM, Cullen MH, et al: Ch1VPP alternating with PAB1OE is superior to PAB1OE alone in the initial treatment of advanced Hodgkin's disease: results of a British National Lymphoma Investigation/ Central Lymphoma Group randomized controlled trial. Br J Cancer 84: 1293-1300, 2001.
25. Levi F, Lucchini F, Negri E and La Vecchia C: Trends in cancer mortality at age 15 to 24 years in Europe. Eur J Cancer 39: 2611-2621, 2003.
26. Kaplan E and Meier P: Non-parametric estimation from incomplete observations. Am Statist Assoc J 53: 457-481, 1958.
27. Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50: 163-170, 1966.
28. Vecchi V, Pileri S, Burnelli R, et al: Treatment of pediatric Hodgkin disease tailored to stage, mediastinal mass and age. An Italian (AIEOP) multicenter study on 215 patients. Cancer 72: 2049-2057, 1993.
29. Duggan DB, Petroni GR, Johnson JL, et al: Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial. J Clin Oncol 21: 607-614, 2003.
30. Bonfante V, Santoro A, Viviani S, et al: Outcome of patients with Hodgkin's disease failing after primary MOPP-ABVD. J Clin Oncol 15: 528-534, 1997.
31. Longo DL, Duffey PL, Young RC, et al: Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin's disease after combination chemotherapy: the low probability for cure. J Clin Oncol 10: 210-218, 1992.
32. Josting A, Rueffer U, Franklin J, et al: Prognostic factors and treatment outcome in primary progressive Hodgkin lymphoma: a report from the German Hodgkin Lymphoma study group. Blood 96: 1280-1286, 2000.
33. Horning SJ, Chao NJ, Negrin RS, et al: High-dose therapy and autologous hematopoietic progenitor cell transplantation for recurrent or refractory Hodgkin's disease: analysis of the Stanford University results and prognostic indices. Blood 89: 801-813, 1997.
34. Chopra R, McMillan A, Linch D, et al: The place of high-dose BEAM therapy and autologous bone marrow transplantation in poor-risk Hodgkin's disease: a single center eight year study of 155 patients. Blood 81: 1137-1145, 1993.